Remove Books Remove Dosage Remove FDA
article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

The FDA Law Blog

Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug. And on X (R.I.P.

Dosage 116
article thumbnail

FTC Continues to Rage Against Device Patent Listings in the Orange Book

The FDA Law Blog

Koblitz — The FTC appears to be on a mission to cleanse the Orange Book of patents it deems improperly listed. For the second time in recent years, the FTC has filed an Amicus Brief explaining exactly which patents should not be in the Orange Book.

FDA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

The FDA Law Blog

Karst — Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny. Last week, the FTC held a Listening Session about the listing of patents in the Orange Book, which concluded with a unanimous vote to issue a Policy Statement.

FDA 105
article thumbnail

Abilify generic availability, cost, and dosage

The Checkup by Singlecare

Abilify first received FDA approval in 2002. Aripiprazole was approved by the FDA in 2015. The FDA requires brand-name medications to undergo extensive testing before being approved. Dosage forms Brand-name and generic Abilify are prescribed at the same dosage and frequency. mL, 960 mg/3.2 mL, 960 mg/3.2

Dosage 52
article thumbnail

The Streams Have Been Crossed: FTC Enters FDA Territory

The FDA Law Blog

” At least that’s this blogger’s reaction to the recent news that FTC sent out Notice letters to 10 different drug companies about the patent information they list in the Orange Book. As FTC explains in a Press Release , the Agency “challenged more than 100 patents” that it believes are improperly or inaccurately listed in the Orange Book.

FDA 59
article thumbnail

FDA Knows Its Own Strength—and It Includes Concentration

The FDA Law Blog

Karst — While the Biologics Price Competition and Innovation Act (“BPCIA”) is inherently distinct from the Hatch-Waxman Act, many of the fundamental concepts FDA adopted as it enacted the Hatch-Waxman Act made their way into FDA’s implementation of the BPCIA. FDA borrowed this definition from 21 C.F.R.

FDA 59
article thumbnail

Happy 40th Anniversary Hatch-Waxman! We’re Celebrating By Providing Access to a New Archive

The FDA Law Blog

Hatch Foundation’s For cheap generic drug prices, you can thank 40 years of Hatch-Waxman We Work For Health’s Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem Tradeoffs’ Race to the Bottom Series FDA CDER Conversations – 40th Anniversary of the Generic Drug Approval Pathway The U.S. Waxman (sadly, Sen.

FDA 59